• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Double transformation of a hematopoietic malignancy and severe associated thrombopathy. Case presentation and review of the literature.

作者信息

Cişleanu Diana, Onisâi Minodora, Vlădăreanu Ana-Maria, Găman Mihaela, Neagul Ana-Maria, Bumbea H, Iova Anamaria, Baluţa Cristina, Cazaceanu Oana, Begu Mădălina, Ilea Anca

机构信息

Hematology Department, Emergency University Hospital Bucharest, Romania.

出版信息

Rom J Intern Med. 2011;49(2):137-44.

PMID:22303605
Abstract

We present the case of a patient with a double transformation during the evolution of chronic hematopoietic malignancy - JAK2 positive chronic myeloproliferative neoplasm; the first transformation had occurred previous to the presentation in our Department, but the second transformation was observed in evolution and it was into a rapidly evolving disease, followed by survival of less than one month. We underline the very poor prognosis -- overall survival of 2.5 years from initial presentation -- a much reduced survival for a chronic myeloproliferative neoplasm, probably due also to multiple associated pathology. Also, the other interesting element of the case is related to the dysfunctional platelets -- hemorrhagic complication at increased platelet count, respectively thrombosis at platelet count under 20000/mmc.

摘要

相似文献

1
Double transformation of a hematopoietic malignancy and severe associated thrombopathy. Case presentation and review of the literature.
Rom J Intern Med. 2011;49(2):137-44.
2
Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.综述:血小板增多症、真性红细胞增多症和 JAK2 突变:慢性骨髓增殖性疾病的表型模拟。
Ann Intern Med. 2010 Mar 2;152(5):300-6. doi: 10.7326/0003-4819-152-5-201003020-00008.
3
The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.JAK2 V617F时代真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化的诊断与管理
Clin Adv Hematol Oncol. 2009 May;7(5):334-42.
4
[New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].[慢性骨髓增殖性疾病中的新型分子标志物。II:JAK2 突变]
Ugeskr Laeger. 2006 Sep 25;168(39):3299-303.
5
Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?骨髓增殖性肿瘤中的白血病转化:与治疗相关还是无关?
Best Pract Res Clin Haematol. 2014 Jun;27(2):141-53. doi: 10.1016/j.beha.2014.07.003. Epub 2014 Jul 19.
6
[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].慢性骨髓增殖性疾病诊断的新方法——JAK2 突变检测
Orv Hetil. 2006 Nov 12;147(45):2175-9.
7
[Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].[原发性血小板增多症。V617F JAK2突变对病理生理学、诊断及预后的作用]
Bull Acad Natl Med. 2007 Mar;191(3):535-48.
8
Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).慢性骨髓增殖性疾病(MPD)、原发性血小板增多症(ET)、真性红细胞增多症(PV)和慢性特发性骨髓纤维化(CIMF)的现行诊断标准。
Pathol Biol (Paris). 2007 Mar;55(2):92-104. doi: 10.1016/j.patbio.2006.06.002. Epub 2006 Aug 21.
9
No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.JAK2基因V617F突变对骨髓纤维化异基因造血干细胞移植(HSCT)后结局无影响。
Biol Blood Marrow Transplant. 2006 Dec;12(12):1350-1. doi: 10.1016/j.bbmt.2006.07.010.
10
A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.真性红细胞增多症中的一个der(18)t(9;18)(p13;p11)和一个der(9;18)(p10;q10),在向真性红细胞增多症后骨髓纤维化转化时伴有增殖性表型。
Cancer Genet Cytogenet. 2007 Jan 15;172(2):107-12. doi: 10.1016/j.cancergencyto.2006.09.015.